123 results
8-K
EX-99.1
IBRX
ImmunityBio Inc
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
of the United States, the regulatory review process and timing thereof, market and prevalence data, potential benefits to patients, potential treatment outcomes
S-3ASR
IBRX
ImmunityBio Inc
17 Apr 24
Automatic shelf registration
5:24pm
, and obligations set forth in the RIPA and related transaction documents;
our expectations regarding the potential benefits of our strategy and technology … ;
our expectations regarding the operation and effectiveness of our product candidates and related benefits;
our ability to utilize multiple modes
S-3ASR
EX-5.1
IBRX
ImmunityBio Inc
17 Apr 24
Automatic shelf registration
5:24pm
, and entitled to the benefits of the Indenture.
4. With respect to Depositary Shares, when: (a) the Board has taken all necessary corporate action
S-3ASR
EX-4.3
IBRX
ImmunityBio Inc
17 Apr 24
Automatic shelf registration
5:24pm
and ratably entitled to the benefits of the Indenture.
Section 2.2 Establishment of Terms of Series of Securities.
At or prior to the issuance of any … the benefits of this Indenture equally and proportionately with any and all other Securities of that Series duly issued hereunder.
The provisions
424B5
yup1po
24 Jul 23
Prospectus supplement for primary offering
5:12pm
8-K
EX-1.1
aci2wfc6
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
EX-1.1
6dks3n
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
424B5
ky87y08
12 Dec 22
Prospectus supplement for primary offering
8:08am